👁 1
💬 0
📄 Extracted Text (615 words)
From: "Erdoes, Mary E"
To: [email protected] <[email protected]>
CC: "Staley, Jes"
Subject: Re: Questions
Date: Wed, 17 Aug 2011 02:46:01 +0000
The answer to the R&D question is how do we access the work they have done on the causes they are passionate about like
education and healthcare.
Many people view them as subject matter experts and we are wondering if they would be willing to share that as part of the
offering
ME
From: Jeffrey Epstein <[email protected]>
To: Erdoes, Mary E
Cc: Staley, Jes
Sent: Tue Aug 16 20:17:45 2011
Subject: Re: Questions
I will get more detailed answers but for now 1. not sure what you mean by R &d ? . no input from the
foundation into investments.. donors can choose from either a custom made portfolio.. or a a choice of silos, and
be able to switch . ( mutual fund concept) 2. mostly initally american. initially , however we should be ready
with an offshore arm. - especailly for vaccines. 3. The donor advised limits influence re grants. but allows great
fliexibility on investments.. anonymoity is varied , according to both gifts to and gifts from 4. pooled is not
really necessary but would be availble for those that preferred it. 5. billions of dollars. the first two years. tens of
billions by year 4. timelimne depends only on jpm ability to organizze, legal, structure internet presence,
staffing. etc 5. exists in perpetuity, with succession controls. 6. there will be acess to the current foundations
pools of targets. but would be looking for both new opportunities with metrics for success.
On Wed, Aug 17, 2011 at 1:43 AM, Erdoes, Mary E wrote:
Here are some questions we have in advance of the meeting, to the extent we can find the answers:
What role will the Gates foundation play vis-a-vis other donors with respect to marketing, sharing of R&D,
grant making and investments?
What is the profile of the potential donors, including residence & tax status? What level of influence will they
want to maintain across investments and grant making? How important is anonymity?
Is pooling of investments and pooled grant making a core feature of the offering?
What is the potential funding amount and what is the anticipated funding rate?
What is the timeline for launch? Is the objective to create a vehicle to exist in perpetuity or is it a thematic
spend-down over time?
Are there specific themes and charities identified for grant making or is there a broad scope of charitable
targets?
These are all generic questions from the team, but to the extent we can get any guidance on some of the
direction, it would be very helpful before the 31st.
EFTA00917611
From Maroon Bells,
Mary
This email is confidential and subject to important disclaimers and
conditions including on offers for the purchase or sale of
securities, accuracy and completeness of information, viruses,
confidentiality, legal privilege, and legal entity disclaimers,
available at http://www.jpmorgan.corn/pages/disclosures/email.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
This email is confidential and subject to important disclaimers and conditions including on offers for the
purchase or sale of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege,
and legal entity disclaimers, available at http://www.jpmorgan.corn/pages/disclosures/email.
EFTA00917612
ℹ️ Document Details
SHA-256
a1db2529a327d288a6ef5664aa7e61e884dd9e024c92a03f028400b6903e03d5
Bates Number
EFTA00917611
Dataset
DataSet-9
Type
document
Pages
2
💬 Comments 0